36 results
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
generated losses since inception. Our income tax expense represents the sum of income taxes payable in the United States, Ireland and Switzerland, offset … by deferred tax credits arising on deferred tax assets generated.
Un-surrendered tax losses are carried forward to be offset against future taxable
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
to the year of disposition or “excess distribution” cannot be offset by any net operating losses for such years, and gains (but not losses) realized
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
the acquisition or even to offset the associated acquisition and maintenance costs.
Depending on the size and nature of future strategic acquisitions … of active income to offset our passive financing income. Therefore, we cannot give any assurance regarding our PFIC status for the current or any future
6-K
EX-99.2
IMCR
Immunocore Holdings plc
7 Nov 23
Current report (foreign)
7:09am
to which we can benefit from U.K. research and development tax relief.
Un-surrendered U.K. tax losses are carried forward indefinitely to be offset … with our preclinical and other research expenses, driven primarily by our other pre-IND programs. These increases were partially offset by a decrease
6-K
EX-99.2
IMCR
Immunocore Holdings plc
10 Aug 23
Current report (foreign)
8:28am
losses are carried forward indefinitely to be offset against future taxable profits, subject to any relevant utilization criteria and restrictions … preclinical candidates, driven primarily by our three pre-IND programs. These increases were partially offset by a decrease of £1.9 million of costs under our
6-K
EX-99.2
0f2i8op pj730601
10 May 23
Current report (foreign)
7:27am
6-K/A
EX-99.1
eeedeq 76
18 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
4:17pm
6-K
EX-99.2
9rabvf
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.1
461e4hb51f3m i3vai
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B5
ex210s260s3a19x
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.1
adlcpxdpi5u5e
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.2
kg4i6lf9c2p92txzl0
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.2
vadaxl44m7m 0r
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.1
zzmp0o ggy82
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.1
84apa8j bgho24
3 Mar 22
Immunocore Reports Full Year 2021 Financial Results
7:01am
6-K
EX-99.2
gkw h5u3u
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.2
i3q mfui4htjg9h
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.2
v0ntj42k9n q8pl8v
12 May 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
20-F
fwu074q3
25 Mar 21
Annual report (foreign)
7:01am